Although
cancer is a
genetic disease, epigenetic alterations are involved in its initiation and progression. Previous studies have shown that reprogramming of
colon cancer cells using Oct3/4, Sox2, Klf4, and cMyc reduces
cancer malignancy. Therefore,
cancer reprogramming may be a useful treatment for chemo- or
radiotherapy-resistant
cancer cells. It was also reported that the introduction of endogenous small-sized, non-coding
ribonucleotides such as
microRNA (miR) 302s and miR-369-3p or -5p resulted in the induction of cellular reprogramming. miRs are smaller than the genes of
transcription factors, making them possibly suitable for use in clinical strategies. Therefore, we reprogrammed
colon cancer cells using miR-302s and miR-369-3p or -5p. This resulted in inhibition of cell proliferation and invasion and the stimulation of the mesenchymal-to-epithelial transition phenotype in
colon cancer cells. Importantly, the introduction of the
ribonucleotides resulted in epigenetic reprogramming of DNA demethylation and
histone modification events. Furthermore, in vivo administration of the
ribonucleotides in mice elicited the induction of
cancer cell apoptosis, which involves the mitochondrial Bcl2
protein family. The present study shows that the introduction of miR-302s and miR-369s could induce cellular reprogramming and modulate malignant phenotypes of human
colorectal cancer, suggesting that the appropriate delivery of functional small-sized
ribonucleotides may open a new avenue for
therapy against human malignant
tumors.